TNBC Biomarker Testing Lags Despite Treatment Advances

Despite advancements in the management of triple-negative breast cancer (TNBC), the selection of treatments continues to depend on a relatively small number of validated biomarkers. While biomarker testing is increasingly integrated into clinical practice for TNBC, the landscape of available markers remains constrained, necessitating further research and development to enhance patient outcomes. The current reliance on a limited set of biomarkers highlights a critical gap between the potential of personalized medicine and its practical application in this aggressive form of breast cancer.

Immunotherapy has emerged as a significant therapeutic avenue for TNBC, particularly for patients whose tumors express programmed death-ligand 1 (PD-L1). PD-L1 expression serves as a key biomarker, identifying a subset of patients likely to benefit from immune checkpoint inhibitors. However, the predictive accuracy of PD-L1 testing can vary, and its utility is further complicated by different scoring systems and antibody clones used across laboratories. This variability underscores the need for standardized testing protocols and more robust biomarkers to reliably predict response to immunotherapy. Beyond PD-L1, other markers are being investigated, including tumor mutational burden (TMB) and microsatellite instability (MSI), which may offer additional insights into a patient's potential response to immune-based therapies.

The development of novel therapeutic strategies for TNBC has been hampered by the heterogeneity of the disease and the lack of specific molecular targets compared to other breast cancer subtypes like hormone receptor-positive or HER2-positive breast cancer. Historically, TNBC has been treated with chemotherapy, which remains a cornerstone of treatment. However, the search for more targeted approaches has intensified, driven by a deeper understanding of the molecular underpinnings of TNBC. This includes exploring inhibitors of DNA repair pathways, androgen receptor signaling, and other oncogenic drivers. Each of these potential targeted therapies requires specific biomarkers to identify patients who are most likely to respond, further emphasizing the critical need for a broader and more precise biomarker panel.

The limitations in current biomarker availability impact not only treatment selection but also the design and interpretation of clinical trials. Trials aiming to evaluate new therapies for TNBC often struggle to recruit appropriate patient populations if robust predictive biomarkers are not readily available. This can slow down the pace of drug development and the translation of promising research findings into clinical practice. Efforts are underway to identify and validate new biomarkers, including those related to tumor microenvironment, genetic mutations, and circulating tumor DNA (ctDNA). The ultimate goal is to move towards a more comprehensive biomarker-driven approach that can guide treatment decisions, improve response rates, and ultimately enhance survival for individuals diagnosed with triple-negative breast cancer. The ongoing research aims to expand the arsenal of validated biomarkers beyond PD-L1 to encompass a wider range of molecular characteristics that can inform personalized treatment strategies.